Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
Status:
Terminated
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This is a single center Phase 1 study to evaluate the safety, pharmacokinetics and
pharmacodynamics of CC-401 in subjects with refractory acute myelogenous leukemia.